News Hope rises for vaccine against hookworm parasite Pivotal trials are being prepared for the Na-GST 1/Al–CpG vaccine, which could help address a parasite affecting hundreds of millions of people.
News Alto raises $120m for resistant depression programme Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
News BioMarin halts Voxzogo trials due to safety signal BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.
News Data builds behind Bayer's Kerendia in kidney disease Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.
News J&J says Inlexzo follow-up 'promising' in bladder cancer Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.
News Regenxbio, Solid report data with Duchenne gene therapies Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.